Pharmacological and structural characterization of vibostolimab, a novel anti-TIGIT blocking antibody for cancer immunotherapy.

Interestingly, the combination of anti-PD-1 and anti-TIGIT antibody treatment showed a trend of additional upregulation of CD226 expression within the CD8 T cells ( figure 8F ), while the frequency of CD226+CD8 T cells was not increased ( figure 8E ).

also in 53,322 other papers